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Abstract
Background: Even though the annual incidence rate of measles has dramatically decreased in
industrialised countries since the implementation of universal immunisation programmes, cases
continue to occur in countries where endemic measles transmission has been interrupted and in
countries where adequate levels of immunisation coverage have not been maintained. The
objective of this study is to develop a model to estimate the average cost per measles case and per
adverse event following measles immunisation using the Netherlands (NL), the United Kingdom
(UK) and Canada as examples.
Methods: Parameter estimates were based on a review of the published literature. A decision tree
was built to represent the complications associated with measles cases and adverse events
following imminisation. Monte-Carlo Simulation techniques were used to account for uncertainty.
Results: From the perspective of society, we estimated the average cost per measles case to be
US$276, US$307 and US$254 for the NL, the UK and Canada, respectively, and the average cost
of adverse events following immunisation per vaccinee to be US$1.43, US$1.93 and US$1.51 for
the NL, UK and Canada, respectively.
Conclusions: These average cost estimates could be combined with incidence estimates and costs
of immunisation programmes to provide estimates of the cost of measles to industrialised
countries. Such estimates could be used as a basis to estimate the potential economic gains of global
measles eradication.
Background
In many industrialized countries, high levels of immuni-
sation over a number of years have led to a dramatic re-
duction in measles incidence. However, measles cases
continue to occur in i) countries, such as the United States
or Canada, where endemic measles transmission have
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been interrupted and cases are linked to importations [1];
and ii) countries, such as Italy and Germany, where ade-
quate levels of immunisation coverage have not been
maintained and measles continues to circulate widely.
These cases of measles can lead to serious complications
and deaths as recently demonstrated in outbreaks in Ire-
land [2], Germany [3] and the Netherlands [4,5]. In addi-
tion to the economic and public health burden that these
cases represent, the maintenance of high levels of vaccine
coverage imposes an additional health and economic bur-
den. The health burden is due to the real and perceived oc-
currence of adverse events following immunisation
(AEFI). The economic burden arises through the cost of
maintaining coverage levels and surveillance pro-
grammes.
In this paper we use a simple model to estimate the aver-
age cost of measles and measles vaccine associated adverse
events, using the Netherlands (NL), the United Kingdom
(UK) and Canada as examples. We then compare our esti-
mates with others available in the literature. This is the
first step in what would be required to estimate the global
cost of measles immunisation and cases in industrialised
countries.
Methods
Estimation of the frequency of measles complications and 
their treatment
A decision tree with the average probabilities used for es-
timating the cost per average case of measles is shown in
Figure 1a. Measles cases are first divided into two distinct
groups, according to whether they seek medical attention
Figure 1
Decision trees. a) measles cases and b) Adverse Event Following Immunisation (AEFI) with measles vaccines. Legend: This
graph shows the proportion of cases with each symptom, complication, sequelae or hospitalisation. A circle corresponds to a
chance node (defined by the probability of the event occurring), a triangle represents an end node. The number at the top of
each branch shows the proportion of each event occurring at that point in the tree. The total proportion of cases in each
group per measles case is written at the right of each branch.
0. 0006% 0. 0001%
0. 0065% 0. 0006%
0
8. 6987% AEFI
0. 0379% 0. 0033%
0. 0008% 0. 0001%
20. 0% 0. 0056%
0. 3219% H o s p ita lis e d ?
80. 0% 0. 0224%
10. 0% 0. 8667%
99. 6323% Vi si t a GP?
90. 0% 7. 8000%
Pr esence of an AEFI ?
91. 3% 91. 3013%
AEFI
None
Encephal i t i s
Anaphyl axi s
Thr om bocyt openi a
SSPE
Febri l e convul si ons
Fever
Yes
Yes
No
Yes
No
b)
a)
2. 2% 0. 041%
32. 4% Hospi t al i sed?
97.8% 1. 842%
15.0% 0. 344%
39. 5% Hospi t al i sed?
85.0% 1. 951%
20. 0% 0. 004%
20.0% Long- t erm sequel ae?
80. 0% 0. 017%
1.9% Hospi t al i sed?
80.0% 0. 086%
7. 5% C o m p lic a tio n s
15. 0% 0. 011%
100. 0% Long- t erm sequel ae?
85. 0% 0. 061%
1.2% Hospi t al i sed?
25. 0% 1. 453%
0. 037% 0. 002%
77. 5% Com pl i cat ed?
92. 5% 71.688%
Seeks m edi cal attenti on?
22. 5% 22. 500%
Me a s l e s c a s e
Repor t ed
Not report ed
Not com pl i cat ed
O titis m e d ia
Pneum oni a and RTI
Febr i l e sei zures
E n c e p h a litis
Thr om bocyt openi a
SSPE
Com pl i cat ed
Yes
No
Yes
No
Yes
No
Yes
Yes
No
Yes
NoBMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/22
Page 3 of 13
(page number not for citation purposes)
Table 1: Distributions used in the simulations to estimate the average costs per measles case.
Complication Consequence Distribution Mean Minimum Maximum
Uncomplicated measles case
% cases not seek-
ing medical atten-
tion
Triangular 22.5 0.0 45.0
Cases not seeing a GP Number of antipy-
retics bought
Exponential 0.2 0.0 1.5
Number of anti-
tussives bought
Tirangular 0.4 0.0 1.0
Number of work-
ing hours missed
Uniform 12 6.0 18.0
Cases seeing a GP Number of visits
to GP
Triangular 1.5 1.0 2.0
Number of antibi-
otics bought
Uniform 1.0 0.0 2.0
Number of antipy-
retics bought
Triangular 1.0 0.0 3.0
Number of anti-
tussives bought
Triangular 1.3 0.0 4.0
Number of work-
ing hours missed
Uniform 16.0 8.0 24.0
Complicated measles cases
% complicated
cases
Triangular 7.5 4.0 12.5
Hospitalised LoS hospital – all
wards
Triangular 4.0 2.0 6.0
LoS Intensive care
Unit
Uniform 5.7 1 10.4
% of hospital time
spent in intensive
care
Triangular 6.5 4.0 8.0
Specific costs for hospitalised complicated cases
Otitis media Frequency (per
100)
Triangular 3.5 2.0 6.0
% hospitalised Triangular 0.2 0.05 0.3
LoS hospital Triangular 1.0 0.5 1.5
Pneumonia and other severe RTI Frequency (per
100)
Uniform 4.3 1.0 8.0
% hospitalised Uniform 15.0 10.0 20.0
LoS hospital Triangular 7.0 4.0 10.0
Encephalitis Frequency (per
100)
Triangular 0.13 0.1 0.2
% hospitalised Fixed 100.0
LoS hospital Triangular 6.0 3.0 9.0
Thrombocytopenia Frequency (per
100)
Uniform 2.1 0.4 5.0
% hospitalised Fixed 100.0
LoS hospital Uniform 3.8 2.0 5.6
Convulsions Frequency (per
100)
Triangular 0.2 0.1 0.4
% hospitalised Triangular 20.0 10.0 40.0
LoS hospital Uniform 2.6 1.0 4.2
SSPE Frequency (per
100,000)
Triangular 3.0 2.0 6.0
Long term sequelae following acute encephalitis
Proportion of
cases with extra
hospitalisation
Uniform 35.0 20.0 50.0
Proportion of
cases with extra
consultations with
a physician
Uniform 15.0 10.0 20.0BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/22
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or not. The minimum value for the proportion of cases
seeking medical attention is largely based on estimates of
the maximal efficiency of reporting systems. It has been
estimated that in the UK [6], US [7,8] and Australia [9],
between 50% and 65% of measles cases are reported to
the authorities in the population [6] or during outbreaks
[8,9] or are medically attended [7]. The UK study, based
on a simple model, comes to the conclusion that an aver-
age of 56% of measles cases was reported between 1957
and 1977. All reported cases must first see a physician to
be reported and thus we can assume that a strict mini-
mum of between 50% and 65% of all measles cases do
seek medical attention. This corresponds to a maximum
proportion of patients not seeking medical attention rang-
ing between 35% and 50%. We choose 45% as the maxi-
mum value for the proportion of patients not seeking
medical attention to take account of the fact that some
cases may seek medical attention but may not be reported
to the authorities as measles. We set the minimum pro-
portion of patients not seeking medical attention to 0%.
Hence, we assume that 22.5% (range 0% to 45%) of mea-
sles cases do not seek medical attention (Figure 1a).
Those that seek medical attention are divided into compli-
cated and non-complicated cases. Based on the weighted
average of five community-based studies, we estimate that
7.5% of cases are complicated [10–14]. Complicated cases
are further divided according to the type of complications
with proportions based on the literature [10–19]. A specif-
ic proportion of measles cases with each complication are
assumed to be hospitalised: an average of 12.5% of severe
respiratory tract infection (RTI), 2.2% of otitis media
Proportion of
cases with chronic
treatment for epi-
lepsy
Uniform 20.0 10.0 30.0
Proportion of
cases missing
school from =
week to < 1
month
Uniform 12.5 5.0 20.0
Proportion of
cases missing
school = 1 month
Uniform 6.0 1.0 11.0
Number of school
days missed
between 1 week
and 1 month
Triangular 11.7 5.0 20.0
Number of school
days missed during
= 1 month
Triangular 37.0 21.0 60.0
Proportion of
cases needing resi-
dential care
Uniform 5.0 1.0 9.0
Long term sequelae following acute febrile convulsions
Proportion of
cases with extra
hospitalisation
Uniform 35.0 25.0 45.0
Proportion of
cases with extra
consultations with
a physician
Uniform 20.0 10.0 30.0
Proportion of
cases with chronic
treatment for epi-
lepsy
Uniform 12.5 8.0 17.0
Variables common to long term sequelae
Average number
of extra hospitali-
sation per year
Triangular 0.33 0.1 0.6
Average number
of extra physician
visits per year
Triangular 3.0 1.0 6.0
Table 1: Distributions used in the simulations to estimate the average costs per measles case. (Continued)BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/22
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(OM), 20% of febrile convulsion and 100% of all other
complications are assumed hospitalised (Table 1). The av-
erage length of stay for all hospitalised cases is estimated
at 4 days with 5.7% of the hospitalisation time spent in in-
tensive care [18–20]. The literature used to estimate the
range of values for all parameters is presented in the Ap-
pendix (see Additional file 1). The distribution effectively
used for all parameters are presented in Table 1. Among
severe complicated cases a small proportion develops
long-term sequelae (Figure 1a). The estimate of the pro-
portion of cases developing Sub-acute Sclerosing PanEn-
cephalitis (SSPE) is taken from a large population-based
study from the UK [21]. An average period from diagnosis
to death for SSPE cases of 2.5 years is used, based on the
same study. Estimates of the incidence of measles associ-
ated encephalitis are based on three studies of passive sur-
veillance data [10,13,16]. Resource use estimates of long-
term neurological sequelae are based on a 12-years fol-
low-up study of 1452 acute encephalopathy, severe febrile
convulsion and control cases [22]. We use the extra fre-
quency of sequelae in the cases compared to the control
group (Table 1a). We assume a life expectancy of 75 years
and an average age for encephalitis and febrile convulsion
cases of 8 years and used a 3% discount rate. The duration
of treatment for epilepsy (recurrent convulsions) is based
on a cross-sectional study of 1,628 epileptic patients tak-
ing medication [23].
Care takers of measles cases that do not seek medical at-
tention are assumed to buy Over-The-Counter (OTC)
drugs and miss some working hours. Non-complicated
cases that do seek medical attention and complicated
non-hospitalised cases are assumed to consult a physi-
cian, be prescribed antibiotics and have their care takers
buy OTC drugs and miss some working hours. For all
non-complicated and non-hospitalised cases, informa-
tion specifically on measles is supplemented by data from
a large study of upper RTI in toddlers attending daycare
centres [24]. The frequency of physician visits and antibi-
otics prescribed in this study agreed well with a smaller
study conducted on measles patients.[25] As there are no
recent studies of the average period of absenteeism caused
by measles cases, we base our estimates on those for chick-
enpox. Chickenpox results in an average of 1.3 days lost
per case (taking account women's employment patterns)
[26]. As measles is more severe, we assume that the aver-
age period of maternal absenteeism is 2 days (ranging
from 1 to 3 days), and for non-reported cases this is re-
duced by 25%, based on the daycare centre study [24]. For
hospitalised cases, maternal absenteeism, adjusted for the
proportion of working women, is assumed to equal the
hospitalisation period.
Estimating the frequency of AEFI and their treatment
A similar model is used for measles AEFI (Figure 1b). That
is, we determine the proportion of vaccinees that are likely
to develop each possible AEFI. We include only those
AEFI thought to be associated with the measles compo-
nent of MMR vaccines based on a thorough review of the
literature [27] and reviews conducted by national advisory
committees on immunization [28,29]. Hence, we exclude
possible AEFI cases of Crohns disease, Guillain Barré syn-
drome and autism as the evidence linking these condi-
tions to measles vaccine is, at best, extremely weak [30–
32]. Similarly, the occurrence of sequelae after encephali-
tis or febrile seizures is not included because they had
been shown not to be related to AEFI with measles con-
taining vaccines [34,35].
It is difficult to attribute AEFI solely to the measles com-
ponent of vaccine because measles immunisation is al-
most always given as the triple vaccine MMR. Here we
assume that any AEFI likely to be caused in part or in total
by the measles component of MMR [27] are wholly attrib-
utable to the measles component. This means that our es-
timate is likely to be an overestimate of the frequency
(and thus cost) of AEFI attributable to the measles compo-
nent of the vaccine.
The frequency of AEFI per vaccinee is considerably lower
than that of complications per measles case and thus is
more difficult to accurately quantify. Nevertheless, for fe-
ver, rashes, encephalitis, thrombocytopenia and febrile
convulsions, comparative studies do exist (see Appendix)
and are used to obtain a feasible range of these estimates
(Table 2). For other AEFI, such as anaphylaxis or SSPE,
case reports and studies of expert opinion are used.
For more common and mild AEFI we only include out-
comes found significant in a large Finnish double-blind
cross-over placebo controlled trial conducted among 581
pairs of twins [35]. For all fever cases, it is estimated that
0.51 days with fever was attributable to the first dose of
MMR. In addition, mild symptoms occurred 16 times less
frequently in children receiving a second dose of MMR
[35]. No other mild symptom was important. Rashes were
also found not to increase significantly after the vaccine
compared to the period before vaccination [36].
We assume that all severe outcomes (anaphylaxis, throm-
bocytopenia, encephalitis) would be hospitalised (see Ta-
ble 2). We also assume that on average 10% of fever cases
would consult a physician (Table 2) [37].
The treatment of complicated hospitalised and non-hos-
pitalised cases is assumed to be the same as for measles
cases. For fever cases, we assume the same duration of pa-
rental absenteeism as for non-reported measles case.BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/22
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Estimating the cost of measles cases and AEFI
We estimate the average cost of each outcome described
above. The overall average cost of a measles case is the
sum of these average costs weighted by the proportion of
measles cases that result in each group (shown at the far
right of each branch in Figure 1).
Costs of an average measles case and of an average case of
measles-associated AEFI are estimated from both the
health care provider (HCP) and wider society perspec-
tives. Costs to the HCP include physician consultations
(including prescribed drugs), hospitalisations (including
intensive care) and of long-term care for SSPE or other se-
quelae. Costs to society (including HCP costs) include the
costs of OTC drugs, maternal absenteeism to care for a sick
child and social costs to care for long-term sequelae. We
exclude indirect costs associated with death and produc-
tivity loss and we do not attempt to put a monetary value
on pain and suffering or measles associated premature
death.
Unit costs for each of the outcomes for each of the study
countries (NL, UK and Canada) are estimated from sever-
al sources. These sources, given in Table 3, include official
statistics [38–42], health economics databases [43–45],
commercial data [46] and reference from the literature
[47].
All reported costs are updated to their 2001 values using
the health Consumer Price Index in each country [43].
The data is then converted to US$ 2001 values with inter-
bank average exchange rates between 01/01/01 and 01/
06/01 [48].
Uncertainty and sensitivity analyses
To take into account the considerable uncertainty sur-
rounding many of the parameter estimates, distributions
are defined for the input parameter values. The model is
run many (10,000) times and on each occasion, a new set
of parameter values for all the uncertain parameters de-
scribed in Tables 123 are randomly selected according to
Table 2: Distributions used in the simulations to estimate the average costs of adverse events per vaccinee.
Complication Consequence Distribution Mean Minimum Maximum
Adverse events (per vaccinee)
Encephalitis Frequency (per
100,000)
Triangular 0.05 0 0.1
% hospitalised Fixed 100.0
LoS hospital Triangular 6.0 3.0 9.0
Convulsions Frequency (per
100,000)
Triangular 28.0 17 34
% hospitalised Triangular 20.0 10.0 40.0
LoS hospital Uniform 2.6 1.0 4.2
% visiting a clinic Fixed 100.0
Number of antipy-
retics bought
Fixed 1.0
Number of anticon-
vulsivants bought
Fixed 1.0
Anaphylaxis Frequency (per
100,000)
Triangular 0.6 0.1 1.0
% hospitalised Fixed 100.0
LoS hospital Uniform 1.5 1.0 2.0
Thrombocytopenia Frequency (per
100,000)
Uniform 3.3 3.1 3.5
% hospitalised Fixed 100.0
LoS hospital Uniform 3.8 2.0 5.6
Fever Frequency (per
100)
Triangular 8.7 2.0 19.0
% visiting a clinic Uniform 10.0 0.0 20.0
Number of antipy-
retics bought
Fixed 1.0
Number of working
hours missed
Uniform 12 6.0 18.0
SSPE Frequency (per
100,000)
Uniform 0.07 0 0.14BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/22
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Table 3: Itemised cost menu (2001 US$) used in the calculations
Item Unit Country Cost Reference (distribution)
Exchange rate (ro 2001 US$) Per local currency Netherlands 0.42 48
UK 1.45 48
Canada 0.67 48
Hospitalisation – general ward Per day Netherlands $ 232.35 64
UK $ 332.97 38
Canada $ 430.23 43
Hospitalisation – intensive care unit Per day Netherlands $ 364.77 43
UK $ 421.07 38
Canada $ 548.76 43
Residential care Per week Netherlands $ 645.81 64
UK $ 406.00 38 (Triangu-
lar(267,415,535)
Canada $ 298.05 39 (Triangular (175.32,
298.05, 420.80)
Visit to the physician Per visit Netherlands $ 15.63 64
UK $ 37.33 38
Canada $ 19.85 39
Antipyretics Per pack Netherlands $ 0.84 64
UK $ 4.06 46
Canada $ 2.98 44 (uniform(1.7, 4.1)
Cough Syrup Per bottle Netherlands $ 4.22 64
UK $ 4.27 46 (uniform(3.9, 4.6)
Canada $ 4.13 44 (triangular(2.7, 4.1,
5.5))
Antibiotics for RTI Per course Netherlands $ 9.29 64
UK $ 4.85 52 (triangular (2.9, 4.4,
7.3))
Canada $ 11.69 44 (triangular (6.8, 10.9,
17.1)
Anticonvulsivant (diazepam for acute 
case)
Per dose Netherlands $ 0.78 64 (Uniform(0.52, 1.04)
UK $ 18.40 45 (Uniform (16.42,
19.41)
Canada $ 3.63 44
Anticonvulsivant (for epilepsy) Per day Netherlands $ 3.53 47 (Triangular (0.6,
4.25, 5.75))
UK $ 2.80 47 (Triangular (1.34,
3.73, 7.47))
Canada $ 1.70 44 (Uniform(0.41, 2.98)
Test to measure anticonvulsivant blood 
levels
Per test Netherlands $ 12.37 47
UK $ 41.95 47
Canada $ 26.00 47 (Uniform (12.00,
40.00))
SSPE – HCP costs Per case Netherlands $ 50,000 Assumed over 2.5
years§BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/22
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their distribution using Monte Carlo sampling. This pro-
vides an outcome distribution for the cost of an average
measles case and allows us to report a mean and 95%
credibility intervals (95% CIs) around our estimates. This
"uncertainty analysis" [49] was performed using @Risk
for excel [50].
By regressing the outcome variable (cost of measles case or
AEFIs) against the values of the input parameters (all
measured in standard deviation changes) it is possible to
explore the sensitivity of the model to the different param-
eters.
Results
The frequency of measles complications and adverse 
events following measles vaccination
The model suggests that an average of 1.9% of all measles
cases are hospitalised (Figure 1a). Most of the complicat-
ed cases are severe respiratory tract infections (39.5%) and
otitis media (32.4%) who make up 20% of all hospital-
ised cases. Cases of thrombocytopenia represent the larg-
est proportion of hospitalised cases (75.3%). This is
because all thrombocytopenia cases are assumed to be
hospitalised and they are relatively frequent (2.1% of cas-
es seeking medical attention).
Figure 1b illustrates that around 8.7% of all vaccinees
would develop AEFI, with 99.6% of these being fever. The
next most frequent AEFI is febrile convulsions. This shows
that most AEFI complications are less severe than that of
measles symptoms. In effect, even with the strong as-
sumption that all severe cases of AEFI cases would be hos-
pitalised, only 0.1% of all vaccinations would lead to
hospitalisation because of AEFI. On a relative scale, this is
almost 200 times less than the proportion of children hos-
pitalised with measles. It should be noted that this does
not mean that the absolute number hospitalised AEFI cas-
es in a population where a large number of children are
vaccinated and a few cases of measles still occur will be
larger than the absolute number of hospitalised measles
cases.
The cost per average measles case
In the following section, the results are presented in the
same order for the Netherlands, UK and Canada. Our es-
timates of the cost to society for an average (95% CI) mea-
sles case are US$276 (174–382), US$307 (202–418) and
US$254 (167–347). HCP costs represent 36% to 43% of
these costs. Costs of hospitalisation are somewhat higher
in Canada (Table 3) explaining the larger proportion of
costs attributable to HCP here. However, our estimates are
similar in all three countries with their 95% CI largely
crossing over (Figure 2a).
The average (95% CI) estimated costs of a typical hospi-
talised case from the HCP perspective are US$967 (604–
1,332), US$1,357 (839–1,877) and US$1,755 (1,085–
2,427) (Figure 2b). The HCP costs represent 85%, 87%
and 91% of the overall costs per hospitalised case to soci-
ety. The average cost of non-hospitalised cases, on the oth-
er hand, is estimated at US$206 (122–293), US$242
(149–338) and US$187 (115–262) with HCP costs repre-
senting 11%, 18% and 14% of the overall costs to society
(Figure 2c).
The cost (95% CI) to the society per average measles en-
cephalitis case, including sequelae, are estimated to be
US$50,500 (22,147–98,031), US$70,059 (30,491–
148,454) and US$132,487 (36,016–132,989) and per av-
erage case resulting in febrile convulsions (including se-
quelae) to be US$6,535 (2,375–16,339), US$9,173
(3,458–23,012) and US$9,544 (2,995–25,776).
UK $ 50,000 Assumed over 2.5
years§
Canada $ 50,000 Assumed over 2.5
years§
SSPE – other costs Per case Netherlands $ 50,000 Assumed over 2.5
years§
UK $ 50,000 Assumed over 2.5
years§
Canada $ 50,000 Assumed over 2.5
years§
Average wage for women Per day Netherlands $ 68.07 40
UK $ 73.06 41
Canada $ 61.77 42
Assumed over 2.5 years§ this is associated with a case of SSPE and assumed to range between US$ 25,000 and US$ 75,000 for both direct and indi-
rect costs.
Table 3: Itemised cost menu (2001 US$) used in the calculations (Continued)BMC Public Health 2002, 2 http://www.biomedcentral.com/1471-2458/2/22
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Figure 2a,2b,2c shows our estimates of the societal and
HCP costs and their 95%CI along with estimates reported
in the literature. The reported societal costs per average
measles case vary between US$180 and US$638, with an
outlier at US$1,188 (Figure 2a). Thus our estimates were
broadly similar to most estimates available in the litera-
ture [51–58]. The proportion of the costs to HCP was also
similar to that reported elsewhere, again with the excep-
tion of that outlier [55]. Only three studies in the litera-
ture have reported the cost per uncomplicated case.
Our estimates of costs from the HCP perspective are closer
to the ones reported by European studies [51,52] than US
studies [53,55]. Indeed, it is noteworthy that many of the
higher estimates derive from US-based studies, which may
partly reflect the generally higher health-care costs in the
US compared with other industrialised countries. The cost
(to the HCP) per hospitalised case was very consistent be-
tween studies [19,20,53,55,60] and comparable to our es-
timates, with one notable (US-based) outlier [18] (Figure
2c). Unfortunately, few previous studies reported the soci-
etal cost per hospitalised case limiting comparison.
The cost of adverse events following measles vaccine
All results are again presented here for the Netherlands,
UK and Canada respectively. From the societal perspec-
tive, we estimate the average (95% CI) cost of AEFI per
vaccinee to be US$ 1.55(0.28–4.35), US$2.08 (0.48–
5.52) and US$1.58(0.41–4.15) with the cost associated
with fever representing 87%, 88% and 84% of the total.
The cost of AEFI per vaccinee is around 150 times less than
the cost of an average measles case. This is largely, though
Figure 2
Societal and health care provider costs a) average case of measles, b) uncomplicated case of measles and c) hospitalized
case of measles from the literature and from our estimates for the Netherlands (NL), the United Kingdom, (UK) and Canada
(Can) for the proportion of cases hospitalized. Legend: (7) The societal cost excludes the cost of encephalitis. Shaded bars cor-
respond to the health care provider costs. Full bars correspond to the societal costs.
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not entirely, because the frequency of AEFI per vaccine is
low compared to the frequency of complications per mea-
sles case. Taking the average (95% CI) cost to society of
each AEFI then we estimate them to be US$18.26 (3.54–
39.41), US$ 24.49 (6.62–48.94) and US$ 18.82 (5.35–
37.24), which is still around 13 times lower than the cost
of an average measles case. This is because the most fre-
quent AEFI is fever. The difference in the country-specific
estimates was mainly due to the difference in the cost per
physician visit and women's salaries. The HCP costs rep-
resented 14%, 24% and 24% of the total cost. It should be
remembered here that these are costs referring to one av-
erage measles case and one average case of measles-asso-
ciated AEFI. These values should not be interpreted as the
costs of measles and AEFIs at the population level.
Figure 3a,3b,3c compares our estimates with those de-
rived from the literature of the cost of AEFI per vaccine
and per event. Taking the average cost per event, it is clear
that our estimates were similar to two studies, [53,54]
though considerably less than another study [55]. Fur-
thermore, the proportion of the costs associated with HCP
was considerably larger in the latter [56], in contrast to the
finding for the cost per measles case. However, when the
average cost per vaccinee is compared, then our estimates
were similar to that latter study [55] where it was assumed
that the treatment of minor adverse events occurred in
2.5% of all vaccination doses whereas 7.5% of vaccinees
had a fever in our estimate which led to a larger denomi-
nator.
Sensitivity analyses
The three most influential variables on costs for the aver-
age cost per measles case were the average number of work
days lost by the mother for a non-hospitalised case, the
proportion of cases not seeking medical attention and the
proportion of encephalitis cases developing sequelae
leading to residential care. The three most influential var-
iables for the average cost per AEFI were the percentage of
fever cases seen in a clinic, the rate of fever and the average
period of absenteeism when a child had to visit a physi-
cian.
Discussion
Although measles is rare in most industrialised countries
it is still important to have up-to-date estimates of the av-
erage cost per measles cases and per measles-associated
AEFI to aid decisions regarding changes to measles control
or elimination programmes. However, the relative scarcity
of both measles and AEFI means that there is a paucity of
recent data and much uncertainty in our resultant esti-
mates. We attempted to minimise this uncertainty by bas-
ing our parameter estimates on a thorough review of the
available literature. Nevertheless, considerable uncertain-
ty remained, which we incorporated into our analysis us-
ing Monte-Carlo Simulation techniques. This meant that
we could not only provide an estimate of the confidence
that we have in our results, but also allowed a systematic
examination of which parameters influenced the results
the most. Finally, we compared our cost estimates to pre-
viously published estimates.
In general there was relatively good agreement between
our estimates of the average cost of measles and AEFI and
those reported in the literature (with one notable excep-
tion) [55]. Whilst this external validation lends some sup-
port to our estimates, it should be noted that some of the
other estimates [53–55] have been based on a similar re-
view of the literature [61,62] and therefore might be ex-
pected to give broadly similar results to ours (after
allowing for inflation).
We have not included stratified costs per age group in our
analysis, as had been done in two studies [52,54], as we
felt that there was insufficient data to further divide them.
Nonetheless, our range of values agreed with the estimates
for individuals aged less than 20 years [52]. Given that
adult measles cases are usually rare, our non-age adjusted
estimate is probably credible.
Accurately estimating the frequency and consequences of
very rare events is difficult and expensive, requiring large-
scale long-term studies, perhaps combined with sophisti-
cated statistical methodologies (see [63] for such an exam-
ple). The results of the sensitivity analyses clearly show,
however, that with the exception of care for encephalitis
cases, these events have very little influence on our esti-
mates of the average cost of measles and measles-associat-
ed AEFI, precisely because they are rare. Instead, the most
influential parameters are concerned with everyday
events, such as the effect of child illness on parental work
patterns, and the proportion of cases that visit a doctor.
Substantial improvements in our estimates of the eco-
nomic impact of measles (and similar infectious disease,
such as chickenpox) can be obtained by concentrating on
these parameters.
Conclusions
The overall cost of measles is given by the average cost of
cases multiplied by the incidence. The average cost esti-
mates provided here will be combined with incidence es-
timates to provide estimates of the cost of measles to
industrialised countries. Such estimates could be used as
a basis to estimate the potential economic gains of global
measles eradication.
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Figure 3
Societal and health care provider Adverse Event Following Immunisation costs. a) per vaccinee and b) per adverse
event from the literature and from our estimates for the Netherlands (NL), the United Kingdom (UK) and Canada (Can). Leg-
end: * estimates are for all adverse events associated with measles-only vaccine ** estimates are for all adverse events associ-
ated with MMR vaccine *** Cost per vaccinee associated with the second dose of MMR only, the frequency of adverse event
with the 2nd dose being assumed to be 10% those of the 1st dose. Shaded bars correspond to the health care provider costs.
Full bars correspond to the societal costs.
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